Accendra Health Inc/va/ (ACH) · Oct 30, 2026 · Delisting
NYSE deficiency — $50.0M minimum average market cap and stockholders’ equity
Accendra Health received another NYSE delisting notice, this time over market capitalization and stockholders’ equity, adding pressure to its turnaround.
Accendra Health is rebuilding around its Apria and Byram home-based-care businesses after selling its former Products & Healthcare Services segment; its latest reported results showed six-month revenue down 8.5%, with a terminated commercial payor contract driving much of the decline while diabetes, ostomy, and urology provided partial offsets. This is a second NYSE warning, not a routine compliance notice. The exchange says Accendra failed both the $50.0 million average-market-capitalization test and the $50.0 million stockholders’ equity test. 〔0〕 The immediate consequence is procedural rather than operational. The shares remain listed, but Accendra must notify the NYSE within 10 business days that it intends to submit a plan, then submit that plan within 45 calendar days showing how it can regain compliance within 18 months. The bigger change is that listing stress has broadened beyond the share-price problem already disclosed earlier this month. On October 6, 2026, Accendra separately reported that its average closing price had fallen below NYSE’s $1.00 threshold and received six months to cure that deficiency. This filing therefore adds a balance-sheet and market-value problem to an already-known price-compliance problem; it is partly known in direction, but materially worse in scope. Accendra offers no concrete cure yet. “Considering” alternatives and promising a business plan do not establish whether the fix will come from operating improvement, a capital raise, restructuring, or another action. The filing also says the NYSE will monitor any accepted plan quarterly, increasing the pressure to show measurable progress. 〔1〕 Bottom line: This does not delist Accendra today, but it confirms that the company’s post-sale turnaround is occurring under escalating exchange-compliance pressure. The new notice makes the listing risk broader and the eventual cure more demanding than the earlier sub-$1 warning alone suggested.
Business plan submission to NYSE, due within 45 calendar days
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!